8-K: Salarius Pharmaceuticals Amends Merger Agreement with Decoy Therapeutics, Faces Nasdaq Listing Deficiency

Salarius Pharmaceuticals amends its merger agreement with Decoy Therapeutics, fixing ownership percentages and addressing a Nasdaq listing deficiency due to insufficient stockholders' equity.

Summary

• Salarius Pharmaceuticals has amended its merger agreement with Decoy Therapeutics, eliminating cash balance adjustments and fixing ownership percentages.
• Legacy Salarius stockholders will retain 14.1% and Decoy stockholders will retain 85.9% of the combined company, before accounting for dilution from a qualified financing.
• The company received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement of $2.5 million for continued listing.
• Salarius has until May 12, 2025, to regain compliance or submit a plan to Nasdaq.
• There is no guarantee that the compliance plan will be accepted or that Salarius will regain compliance and maintain its Nasdaq listing.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the merger agreement amendment provides clarity, the Nasdaq listing deficiency raises concerns about the company's financial health.

Positives

• The amendment to the merger agreement provides clarity on the ownership structure of the combined company.
• Salarius has the opportunity to regain compliance with Nasdaq listing requirements by May 12, 2025, or through a compliance plan.

Negatives

• Salarius is not in compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million.
• There is no guarantee that Salarius will regain compliance with Nasdaq listing requirements.

Risks

• The merger is contingent on completing a qualified financing of at least $6.0 million.
• Failure to regain compliance with Nasdaq listing rules could result in delisting.
• The company's compliance plan may not be accepted by Nasdaq.
• The company may not be able to accurately estimate its net cash at closing or manage its operating expenses.

Future Outlook

The company intends to regain compliance with Nasdaq listing standards, but there is no guarantee of success. The merger with Decoy Therapeutics is expected to proceed, subject to certain conditions, including the completion of a qualified financing.

Industry Context

The pharmaceutical industry is highly regulated and requires significant capital investment. Mergers and acquisitions are common strategies for companies to expand their product pipelines and market reach. Maintaining Nasdaq listing is crucial for access to capital markets and investor confidence.

Comparison to Industry Standards

• Many small-cap pharmaceutical companies struggle to maintain Nasdaq listing compliance due to the high costs of research and development and the long timelines for drug approval.
• A comparable company, Genprex, Inc., received a similar Nasdaq notice in 2023 for failing to meet the minimum bid price requirement.
• The $6 million qualified financing requirement is typical for small biotech mergers to ensure sufficient capital for ongoing operations and clinical trials.

Stakeholder Impact

• Shareholders face the risk of delisting if Salarius fails to regain compliance with Nasdaq listing rules.
• Employees of both Salarius and Decoy may experience uncertainty during the merger process.
• The merger could impact the company's relationships with suppliers and customers.

Next Steps

• Salarius must regain compliance with Nasdaq listing requirements by May 12, 2025, or submit a compliance plan.
• The company needs to complete a qualified financing of at least $6.0 million to proceed with the merger.
• Salarius and Decoy will work towards satisfying the remaining conditions for closing the merger.

Key Dates

Keywords

Merger Agreement, Salarius Pharmaceuticals, Decoy Therapeutics, Nasdaq, Compliance, Stockholders' Equity, Delisting, Qualified Financing